Skip to main content
. Author manuscript; available in PMC: 2020 Jul 20.
Published in final edited form as: Ann Thorac Surg. 2019 Dec 14;109(4):1019–1025. doi: 10.1016/j.athoracsur.2019.10.061

Figure 2:

Figure 2:

A) Concept of Mass Spectroscopy to Assess the Glycolytic Pathway Intermediates 13C-labeled glucose tracing strategy. Isotopically labeled 13C carbons (grey) can be distinguished from naturally occurring 12C (open circles) by mass spectrometry. The incorporation of [U-13C]glucose into unlabeled glucose pools is expressed as percent enrichment. 3PG-3-phosphoglycerate; PEP-phosphoenolpyruvate; OAA-oxaloacetate B) Results of Serum Glucose Enrichment with 13C Glucose Serum enrichment of glucose m+6 ([U-13C]) from the time of initial infusion. Data are expressed as average and SEM. Glucose m+6-represents the % of glucose molecules that all of the carbons in glucose are labeled 13C.